Systemic Therapy for Metastatic Renal Cell Carcinoma

This publication has 68 references indexed in Scilit:

• Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
  The Lancet, 2007
• Sorafenib in Renal Cell Carcinoma
  Clinical Cancer Research, 2007
• Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
  New England Journal of Medicine, 2007
• Cancer Statistics, 2007
  CA: A Cancer Journal for Clinicians, 2007
• Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A CALGB Intergroup Phase II Study
  Transplantation and Cellular Therapy, 2006
• Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
  Nature Medicine, 2005
• A Phase II Trial of Gefitinib (Iressa, ZD1839) in Stage IV and Recurrent Renal Cell Carcinoma
  Clinical Cancer Research, 2004
• The biology of VEGF and its receptors
  Nature Medicine, 2003
• Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase
  Journal of Medicinal Chemistry, 2003
• Role of transforming growth factor-alpha in von Hippel- Lindau (VHL)-/- clear cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis
  Proceedings of the National Academy of Sciences, 2001